May 12, 2014

Perrigo on Monday announced that it received approval from the Food and Drug Administration for azelastine hydrochloride nasal spray (0.15%), a generic version of Astepro. The drug is indicated for people ages 12 years and older and is used to treat nasal symptoms brought on by seasonal allergies or environmental irritants.

April 21, 2014

By adding complementary specialty medication offerings to their generic drug businesses, manufacturers can add instant value and counteract the margin compression that is currently occurring as a result of high generic drug utilization.

March 26, 2014

Perrigo announced that its Nutritionals segment is partnering with KanPak to manufacture store brand adult nutritional drinks comparable to Ensure products.

March 18, 2014

The Consumer Healthcare Products Association on Tuesday announced the members of the CHPA Educational Foundation Board during the association’s Annual Executive Conference held here.

March 13, 2014

Perrigo announced the launch of methazolamide tablets, the generic version of Neptazane tablets. The product is a component of the rights the company received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals and its affiliates last year.

March 10, 2014

Two Rx-to-OTC switches in the past year may serve as a harbinger of what the Food and Drug Administration will consider “switch” worthy.

February 28, 2014

Perrigo on Friday announced that it has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global for $51 million in cash.

January 24, 2014

Perrigo announced that it received final approval from the Food and Drug Administration for repaglinide tablets — a generic version of Prandin tablets.

January 15, 2014

Perrigo on Tuesday announced that it has received final approval for its abbreviated new drug application for fluocinonide cream 0.1%, the generic equivalent to prescription-only Vanos Cream 0.1%.

December 18, 2013

Perrigo has finalized its acquisition of Elan Corp., Perrigo said Wednesday.

December 13, 2013

The Irish High Court has approved Perrigo's pending acquisition of Irish drug maker Elan, the companies said Friday.

November 22, 2013

The shareholders of Elan Corp. approved the acquisition of the company by Perrigo Co. at two special meetings.

November 20, 2013

Drug maker Perrigo has filed with the Food and Drug Administration for approval of a generic topical ointment for treating acne in adolescents and adults, the company said Wednesday.

November 4, 2013

Perrigo on Friday initiated a voluntary, nationwide product recall to the retail level of 18 batches of its acetaminophen infant suspension liquid.

September 23, 2013

The Food and Drug Administration has approved a drug made by Perrigo Co. for treating heart disease, the company said Monday.

September 20, 2013

Perrigo Co. has hired a former Food and Drug Administration official for its regulatory department, the drug maker said.

September 10, 2013

Perrigo announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug application for cetirizine hydrochloride oral solution USP, 1 mg/mL, bubble gum flavored, the store brand equivalent to Children's Zyrtec Allergy Syrup.

August 12, 2013

Perrigo Co. announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug applications for fluocinolone acetonide scalp oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Scalp Oil, and fluocinolone acetonide topical oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Body Oil.

August 12, 2013

Teva Pharmaceutical and Perrigo Co. announced the launch of the generic equivalent to Temodar (temozolomide). Teva will manufacture, market and distribute the product in the United States, and both companies will equally share in the cost and profitability of the product in the country.

July 31, 2013

The Food and Drug Administration has approved a Perrigo generic drug for treating dermatitis, the company said Wednesday.

July 29, 2013

U.S.-based drug maker Perrigo Co. will buy Ireland's Elan Corp. for $8.6 billion, the companies said.

July 19, 2013

Perrigo announced the tentative approval for repaglinide tablets, a generic version of Novo Nordisk's Prandin, used to treat Type 2 diabetes.

June 25, 2013

Tyco Integrated Security on Tuesday announced it has teamed up with Perrigo Nutritionals to develop a theft-resistant infant formula container.

June 24, 2013

Perrigo on Monday promoted Emily Hiller to assistant category manager for the category management team at Perrigo Nutritionals in Gordonsville, Va.